← All stories
Markets
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
2 outlets - including Investing and Statnews - are covering this story. A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.
Covered by 2 outlets
All coverage · 2 articles
Investing.com Stock Market
·1h ago
Vaccine stocks jump on Moderna’s melanoma vaccine trial results
STAT News
·1h ago
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.